ANL 34.20 Increased By ▲ 0.08 (0.23%)
ASC 15.15 Increased By ▲ 0.35 (2.36%)
ASL 24.25 Decreased By ▼ -0.07 (-0.29%)
AVN 93.25 Increased By ▲ 2.03 (2.23%)
BOP 7.86 Increased By ▲ 0.07 (0.9%)
BYCO 10.03 Decreased By ▼ -0.18 (-1.76%)
DGKC 121.15 Decreased By ▼ -0.35 (-0.29%)
EPCL 54.42 Decreased By ▼ -0.73 (-1.32%)
FCCL 24.10 Decreased By ▼ -0.14 (-0.58%)
FFBL 28.11 Increased By ▲ 0.01 (0.04%)
FFL 16.11 Decreased By ▼ -0.05 (-0.31%)
HASCOL 9.50 No Change ▼ 0.00 (0%)
HUBC 77.85 Increased By ▲ 0.15 (0.19%)
HUMNL 6.45 Decreased By ▼ -0.02 (-0.31%)
JSCL 21.48 Increased By ▲ 1.08 (5.29%)
KAPCO 39.50 Decreased By ▼ -0.50 (-1.25%)
KEL 3.79 Decreased By ▼ -0.03 (-0.79%)
LOTCHEM 15.90 No Change ▼ 0.00 (0%)
MLCF 45.70 Decreased By ▼ -0.45 (-0.98%)
PAEL 35.22 Decreased By ▼ -0.68 (-1.89%)
PIBTL 10.14 Decreased By ▼ -0.01 (-0.1%)
POWER 9.08 Decreased By ▼ -0.06 (-0.66%)
PPL 84.83 Decreased By ▼ -0.37 (-0.43%)
PRL 24.20 Decreased By ▼ -0.10 (-0.41%)
PTC 9.64 Increased By ▲ 0.14 (1.47%)
SILK 1.43 Decreased By ▼ -0.02 (-1.38%)
SNGP 41.12 Decreased By ▼ -0.28 (-0.68%)
TRG 176.03 Increased By ▲ 11.02 (6.68%)
UNITY 33.20 Increased By ▲ 0.55 (1.68%)
WTL 1.69 Decreased By ▼ -0.04 (-2.31%)
BR100 4,897 Increased By ▲ 25.81 (0.53%)
BR30 25,803 Increased By ▲ 217.6 (0.85%)
KSE100 45,526 Increased By ▲ 126.48 (0.28%)
KSE30 18,623 Increased By ▲ 89.7 (0.48%)

Coronavirus
VERY HIGH
Pakistan Deaths
16,600
14824hr
Pakistan Cases
772,381
549924hr
Sindh
274,196
Punjab
276,535
Balochistan
21,127
Islamabad
70,984
KPK
108,462
Business & Finance

Regeneron signs $450mn contract with US govt for COVID-19 therapy

  • The cocktail, REGN-COV2, is in separate clinical trials assessing its effectiveness in preventing and treating COVID-19, the company said.
  • The agreement covers a fixed number of bulk lots that are intended to be completed in the fall of 2020, the company said.
07 Jul 2020

Regeneron Pharmaceuticals Inc said on Tuesday the US government signed a $450 million contract with the drugmaker to make and supply its potential double antibody cocktail for COVID-19.

The cocktail, REGN-COV2, is in separate clinical trials assessing its effectiveness in preventing and treating COVID-19, the company said.

Regeneron signed the contract with the US Department of Health and Human Services' (HHS) Biomedical Advanced Research and Development Authority (BARDA) and the Department of Defense. The doses manufactured under the project will be owned by the federal government.

The contract comes under the government's "Operation Warp Speed" program, aimed at accelerating access to vaccines and treatments to fight the coronavirus.

The government will support manufacturing REGN-COV2 for immediate use in the country, if the clinical trials are successful and the US Food and Drug Administration grants emergency use authorization (EUA) or product approval.

The agreement covers a fixed number of bulk lots that are intended to be completed in the fall of 2020, the company said.

It expects a range of 70,000 to 300,000 potential treatment doses or 420,000 to 1,300,000 prevention doses to be available from these lots, with initial doses to be ready as early as end of summer.

If EUA or product approval is granted, the government has committed to making doses from these lots available to Americans at no cost and would be responsible for their distribution, Regeneron said.

Separately, the US government on Tuesday awarded a $1.6 billion grant to Novavax Inc, the biggest yet from Operation Warp Speed, to cover testing, manufacturing and sale of a potential coronavirus vaccine in the country.